Nesiritide, a recombinant BNP, was granted approval by the US Federal Drug Administration (FDA) in 2001 for the management of acute HF based on its anticongestive effects comprising a decrease in pulmonary capillary wedge pressure and early relief of shortness of breath [50]. This evidence concerns the gene NPPB and hydrops fetalis.